Skip to main content
. 2023 Jul 10;120(29):e2214320120. doi: 10.1073/pnas.2214320120

Fig. 4.

Fig. 4.

Cancer vaccines using lipoplex in mice. (A) Expression of fLuc in the spleen 24 h after i.v. injection of lipoplex. n = 4. (B) Activation of DC in the spleen 24 h after i.v. injection of lipoplex. n = 4. The expression level of CD86 in CD11c positive splenocytes. (C) CTL immunity against OVA 7 d after mRNA vaccination, evaluated by the in vivo CTL assay. n = 4. (D) Serum levels of IL-6 were measured using ELISA 6 h and 24 h after i.v. injection of lipoplexes. n = 4. n.d.: not detected. (E) Prophylactic model of subcutaneously inoculated lymphoma expressing OVA, treated using OVA mRNA. n = 6 for untreated, n = 4 for the other two groups. (F) Therapeutic model of subcutaneously inoculated lymphoma expressing OVA, treated using OVA mRNA. n = 4. (G) Therapeutic model of subcutaneously inoculated melanoma, treated using Trp2 mRNA. †Average tumor volume was not shown at later time points because of the death of one or more mice. n = 8. *P < 0.05 versus 0 tooth. (E−G) The first chart from the left shows the average tumor volumes in each group. The second to fourth charts from the left shows the tumor volume of individual mice (Right). (F) The right figure shows the mouse survival. (B−F) OVA mRNA dose for each injection was 5 μg, and tooth dose was 0.23 μg for 1 tooth, 0.70 μg for 3 teeth, and 1.2 μg for 5 teeth, respectively. (G) The dose was 10 μg for Trp2 mRNA and 0.34 μg for a tooth.